fda statement on compounded semaglutide Is Safe? FDA and Novo Nordisk Warn
Description
Higher doses produce stronger appetite suppression and greater weight loss, which is why the maintenance dose for obesity (2.4 mg weekly) is higher than the typical diabetes maintenance dose (1 mg weekly)

Janoshik Website

Dual Agonists Under Investigation Tirzepatide (Mounjaro) was approved by the FDA on May 13, 2022 for the treatment of type 2 diabetes in adults, making it the first and only GIP/GLP-1 receptor agonist

Its extremely important to ensure the quality of the GLP-1 treatment before using it
